Pembrolizumab Plus Weekly Paclitaxel, With Or Without Bevacizumab, Improves OS in Patients With Platinum-Resistant Recurrent Ovarian Cancer By Ogkologos - April 23, 2026 290 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENGOT-ov65/KEYNOTE-B96 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Molecular Analysis for Precision Oncology Congress 2023, 4–6 October 2023 Paris,... September 26, 2023 ΚΑΡΚΙΝΟΣ ΟΥΡΟΔΟΧΟΥ ΚΥΣΤΕΩΣ March 8, 2019 Mediterranean Diet Associated with a Higher Probability of Response in Patients... February 28, 2023 Dr Ian Walker on Smoking: ‘An unequal burden, but a fixable... March 31, 2023 Load more HOT NEWS Adding Talazoparib to Enzalutamide Prolongs Imaging-Based PFS in Metastatic Androgen Pathway Modulation-Sensitive Prostate... ESMO Publishes First-Ever Guidance on Validation Requirements for AI-Based Biomarkers in... Man Pushes Daughter To Safety Before Speeding Car Hits Him Instead:... Happy 29th Birthday OncoLink!
